Sequoia Financial Advisors LLC Trims Stock Position in Zimmer Biomet Holdings, Inc. $ZBH

Sequoia Financial Advisors LLC lessened its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 7.6% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 81,208 shares of the medical equipment provider’s stock after selling 6,677 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Zimmer Biomet were worth $7,999,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Legacy Wealth Asset Management LLC lifted its holdings in Zimmer Biomet by 2.3% in the third quarter. Legacy Wealth Asset Management LLC now owns 4,670 shares of the medical equipment provider’s stock valued at $460,000 after acquiring an additional 106 shares during the period. Global Retirement Partners LLC increased its holdings in shares of Zimmer Biomet by 7.0% during the 3rd quarter. Global Retirement Partners LLC now owns 1,686 shares of the medical equipment provider’s stock valued at $166,000 after purchasing an additional 111 shares in the last quarter. Generali Asset Management SPA SGR lifted its stake in shares of Zimmer Biomet by 0.9% in the 3rd quarter. Generali Asset Management SPA SGR now owns 14,232 shares of the medical equipment provider’s stock valued at $1,402,000 after purchasing an additional 122 shares during the period. Brookstone Capital Management boosted its holdings in Zimmer Biomet by 1.3% during the third quarter. Brookstone Capital Management now owns 9,350 shares of the medical equipment provider’s stock worth $921,000 after buying an additional 123 shares in the last quarter. Finally, TD Private Client Wealth LLC grew its position in Zimmer Biomet by 14.0% during the third quarter. TD Private Client Wealth LLC now owns 999 shares of the medical equipment provider’s stock valued at $98,000 after buying an additional 123 shares during the period. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Stock Performance

NYSE ZBH opened at $87.42 on Monday. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.43 and a quick ratio of 1.39. The stock’s 50 day simple moving average is $91.59 and its 200-day simple moving average is $96.50. The company has a market cap of $17.32 billion, a PE ratio of 21.64, a price-to-earnings-growth ratio of 2.23 and a beta of 0.62. Zimmer Biomet Holdings, Inc. has a 1-year low of $85.33 and a 1-year high of $114.44.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 EPS for the quarter, topping the consensus estimate of $1.88 by $0.02. The firm had revenue of $2 billion during the quarter, compared to analysts’ expectations of $2.01 billion. Zimmer Biomet had a return on equity of 12.85% and a net margin of 10.05%.The firm’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same period in the previous year, the business earned $1.74 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Tuesday, December 30th will be given a dividend of $0.24 per share. The ex-dividend date is Tuesday, December 30th. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. Zimmer Biomet’s payout ratio is presently 23.76%.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on ZBH shares. Baird R W lowered shares of Zimmer Biomet from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 16th. Evercore ISI upgraded Zimmer Biomet from an “in-line” rating to an “outperform” rating and increased their price target for the stock from $94.00 to $120.00 in a research report on Monday, January 5th. UBS Group dropped their price objective on Zimmer Biomet from $96.00 to $88.00 and set a “sell” rating on the stock in a report on Thursday, November 6th. Johnson Rice set a $112.00 target price on Zimmer Biomet in a research note on Wednesday, November 5th. Finally, Robert W. Baird reissued a “neutral” rating and issued a $100.00 price target (down previously from $117.00) on shares of Zimmer Biomet in a research note on Tuesday, December 16th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, eleven have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, Zimmer Biomet currently has an average rating of “Hold” and a consensus price target of $107.33.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.